Elanco Animal Health (Elanco Animal Health) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Elanco Animal Health is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Elanco Animal Health's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elanco Animal Health's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Elanco Animal Health's Risk Assessment falls into.

Elanco Animal Health (NYSE:ELAN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Elanco Animal Health Risk Assessment Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanco Animal Health (Elanco Animal Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

5EA:Germany

Address

2500 Innovation Way, Greenfield, IN, USA, 46140

Website

https://www.elanco.com

Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Executives

Grace Mcardle	officer: EVP, MANUFACTURING AND QUALITY	2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington	officer: See remarks	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
R David Hoover	director	C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Jeffrey N Simmons	director, officer: Pres., Chief Executive Officer	2500 INNOVATION WAY, GREENFIELD IN 46140
John P Bilbrey	director
Rajeev A. Modi	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen	director	C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Michael J Harrington	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Brabander Ellen De	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger	officer: Ex VP, Gen Counsel & Corp Sec	C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia	director	11690 N.W. 105TH STREET, MIAMI FL 33178
William F Doyle	director
Uncas Gp Llc	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019